0001209191-22-024290.txt : 20220413
0001209191-22-024290.hdr.sgml : 20220413
20220413163615
ACCESSION NUMBER: 0001209191-22-024290
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220411
FILED AS OF DATE: 20220413
DATE AS OF CHANGE: 20220413
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lachey Jennifer
CENTRAL INDEX KEY: 0001808322
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39264
FILM NUMBER: 22825064
MAIL ADDRESS:
STREET 1: C/O KEROS THERAPEUTICS, INC.
STREET 2: 99 HAYDEN AVENUE, SUITE 120, BUILDING E
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Keros Therapeutics, Inc.
CENTRAL INDEX KEY: 0001664710
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E)
STREET 2: LEDGEMONT TECHNOLOGY CENTER
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-513-8774
MAIL ADDRESS:
STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E)
STREET 2: LEDGEMONT TECHNOLOGY CENTER
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-04-11
0
0001664710
Keros Therapeutics, Inc.
KROS
0001808322
Lachey Jennifer
C/O KEROS THERAPEUTICS, INC.
99 HAYDEN AVENUE, SUITE 120, BUILDING E
LEXINGTON
MA
02421
0
1
0
0
Chief Scientific Officer
Common Stock
2022-04-11
4
M
0
5300
0.30
A
91000
D
Common Stock
2022-04-11
4
S
0
1417
61.37
D
89583
D
Common Stock
2022-04-11
4
S
0
1009
62.32
D
88574
D
Common Stock
2022-04-11
4
S
0
2315
63.50
D
86259
D
Common Stock
2022-04-11
4
S
0
559
64.15
D
85700
D
Employee Stock Option (right to buy)
0.30
2022-04-11
4
M
0
5300
0.00
D
2028-03-25
Common Stock
5300
71405
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.97 to $61.935 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.975 to $62.97 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.975 to $63.865 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.00 to $64.49 inclusive.
Immediately exercisable.
/s/ Keith Regnante, Attorney-in-Fact
2022-04-13